Scarica l'app Stockscreener
25.25
46.61%
-22.30
Dice Therapeutics Inc Borsa (DICE) Ultime notizie
DICE Therapeutics Inc. (DICE) Peer Comparison – Compare with Others - Value Research
Ambros Therapeutics Announces Appointments of John C. Jacobs and Scott Robertson to Board of Directors - The Manila Times
Autoimmune Treatment Market Report Examines Industry Trends, Growth Drivers And Future Outlook - openPR.com
DHI Group (DHX) Stock Sees Fair Value Lift As Analysts Weigh ClearanceJobs And Dice - Yahoo Finance
Segment Overview and Major Growth Areas in the Urokinase Market - openPR.com
CAPR Stock Drop: Capricor Therapeutics Clinical Data Leads to 64% Stock Drop and Securities Fraud Class Action for Investors - PR Newswire
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology - Eli Lilly and Company
A 'Made in the USA' Monopoly edition cost twice as much to build — and no US factory could even make the dice - Yahoo Finance
An InventHelp 123Invent Client Develops New Money Themed Dice Game (LBT-9813) - Yahoo Finance
The EU rolls dice by setting unambiguous parameters for Satcos operating in 2GHz - Yahoo Finance
Tech Professionals Find Relevant Roles Faster with Dice’s LLM Connector - Yahoo Finance
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188% - The Motley Fool
Morningstar Sees SpaceX Worth Half Its IPO Price - thedeepdive.ca
OpenAI Files Confidential S-1 With SEC, Targeting IPO as Soon as Q4 - thedeepdive.ca
SpaceX Cuts IPO Valuation Target to $1.8 Trillion After Investor Feedback - TheDeepDive.ca
TWO DICE SECURES STRATEGIC INVESTMENT FROM OAK VIEW GROUP - Yahoo Finance
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire
Russia is about to roll the dice on crypto regulation. Here’s its playbook - Yahoo Finance
Jim Cramer on JetBlue Airways: “It’s a Dice Roll, and I Don’t Like Dice Rolls” - Yahoo Finance
EA Slashes Battlefield Headcount In a Pivot to AI - Yahoo Finance
Burnout, layoffs, 'ghost jobs' in Dice's 2026 tech survey - Stock Titan
Muted and missing M&As: JPM deals absent in 2026 - bioworld.com
Baron of Dice Answers the Questions Players Keep Asking - Yahoo Finance
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs - BioPharma Dive
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha
Boyd Gaming reveals $160M revamp for Par-A-Dice Casino - Yahoo Finance
IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes - American Heart Association Journals
Journal of the European Academy of Dermatology and Venereology - Wiley Online Library
Don't Buy Summit Therapeutics Until This Big Thing Happen - The Motley Fool
Big pharma drives surge in biopharma job cuts in 2025 - BioWorld News
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy - Business Wire
RNA Therapeutics Market Size to Reach USD 26.13 Billion by 2034 - BioSpace
Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight - PR Newswire
Formulation specialist Azurity to lay off 75 amid plans to sunset Massachusetts plant - Fierce Pharma
Fever Acquires Ticketing Platform Dice - Yahoo Finance
Forward Therapeutics, the first biotech from Curie.Bio, raises $50M for oral small molecules in immunology - Endpoints News
DHI Group Inc (DHX) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Focus - Yahoo Finance
15 Best Growth Stocks to Buy for the Next 3 Years - Insider Monkey
Dice Therapeutics Stock Price, News & Analysis - Stock Titan
Biopharma restructurings reflect strategy of short-term pain for long-term gains - BioWorld News
10 Best Low Volatility Stocks to Buy Now - Insider Monkey
The top 10 pharma R&D budgets for 2024 - Fierce Biotech
Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25) - GlobeNewswire
Sage lawsuit enforces standstill as board evaluates Biogen offer - BioWorld News
The top 10 biopharma M&A deals of 2024 - Fierce Pharma
Gambling.com Rolls The Dice On OddsJam's Parent; $80M Upfront Consideration For Instant Revenue Boost - Yahoo Finance
Combos, New MOAs, And Oral Formulations Of Injectables: Lilly’s Immunology Strategy - insights.citeline.com
Why Did Eli Lilly Stock Fall 6%? - Trefis
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products - Eli Lilly and Company
Mounjaro To Lead Eli Lilly’s Q3 Growth - Trefis
Lilly’s Ebglyss enters US atopic dermatitis market with FDA nod - BioWorld News
Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies - Business Wire
Lilly to Test Zepbound in Psoriasis to Follow Up on Weight-Loss Success - Bloomberg.com
AbbVie acquires Cerevel Therapeutics for $45 per share - TechTarget
Avalo Therapeutics Appoints Dr. Mittie Doyle as Chief Medical Officer - citybiz
DICE Therapeutics (NASDAQ: DICE)Share Price - intelligentinvestor.com.au
EX-99.1 - SEC.gov
Lilly to buy Morphic in $3B bet on inflammation drug - BioPharma Dive
Periodontal Therapeutics Market Size Report, 2024-2030 - Grand View Research
Arlington's Sands Capital raises hefty sum for third life sciences fund - The Business Journals
Life Sciences Group Of The Year: Fenwick - Law360
Changing Faces: Pharma and biotech hires from January 2024 - pharmaphorum
Perpetual aims to be peptide powerhouse - BioWorld News
Fierce Biotech M&A Tracker 2023: BMS, AbbVie drop billions for neuropsychiatry biotechs - Fierce Biotech
U.S. Psoriasis Treatment Market Size, Share | Report [2030] - Fortune Business Insights
Immunomodulators Market Will Grow at CAGR of 15.3% By 2032 - Precedence Research
EX-99 - SEC.gov
GLP-1 drugs carry Lilly, Novo; Moderna tops revenue expectations - Medical Marketing and Media
Biopharma IPO class of 2023: Performance down 27% - BioWorld News
Top 10 Women’s Health Companies | Medical and Wellness Concerns - Market.us Media
Eli Lilly acquires Point Biopharma for $1.4B: Employee rights - Samfiru Tumarkin LLP
0.71%
2.84%
Capitalizzazione:
|
Volume (24 ore):